



## Original Research Article

## Comparison of various regimens of itraconazole in treatment of acute vulvovaginal candidiasis

Piyush Prabhat<sup>1</sup>, Lalita Mayadeo<sup>2</sup>, Harshal Mahajan<sup>3</sup>, Dhiraj Dhoot<sup>3,\*</sup>

<sup>1</sup>Dept. of Obstetrics and Gynecology, Jeevak Hospital, Fortis Raheja Hospital, Mumbai, Maharashtra, India

<sup>2</sup>Dept. of Obstetrics and Gynecology, Desai Hospital, Mumbai, Maharashtra, India

<sup>3</sup>Dept. of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India



## ARTICLE INFO

## Article history:

Received 14-03-2021

Accepted 23-03-2021

Available online 11-06-2021

## Keywords:

Itraconazole

Acute

Vulvovaginal candidiasis

Non-albicans candida

## ABSTRACT

**Introduction:** One of the most striking change in the current scenario is the increasing occurrence of non-albicans vulvovaginal candidiasis (VVC), which is considered as the major cause of recurrence, relapse and chronic VVC in India. In the present study we evaluated the effectiveness of three different regimens of itraconazole in the treatment of acute VVC.

**Materials and Methods:** The present randomised, three arm comparative clinical study involved 123 women aged 18 years or above with symptomatic acute VVC. These patients were randomised (41 patients in each group) to receive either itraconazole 200 mg twice daily for 1 day (group I), 200 mg twice daily for 2 days (group II) or 100 mg twice daily for 3 days (group III). Effectiveness was evaluated on the basis of clinical cure (total symptom score), mycological cure (negative KOH test).

**Results:** All the groups were effective in relieving signs and symptoms ( $p < 0.05$ ), but on comparison between all groups, there was statistical difference between Group II and Group I & III ( $p < 0.05$ ) and Group III & I ( $p < 0.05$ ). Complete cure i.e. disappearance of signs and symptoms and negative KOH test was maximum in group II (44%) as compared to groups I (12%) and III (17% of the patients). Relapse was least in seen in 11 patients (27%) in Group I, 3 patients (7%) in Group II and 7 patients (17%) in Group III. All the 3 regimens were well tolerated.

**Conclusion:** In the present study, 2 day high dose itraconazole therapy was found to have better effectiveness compared to conventional regimens. Longer duration of therapy might be required to attain even better cure rates, especially when the incidence of Non Albicans vulvovaginal candidiasis is rising in all parts of the country.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### 1. Introduction

Vaginitis is a common complaint of adult female patients attending gynecological practice and vulvovaginal candidiasis (VVC) is the most common presenting infection. Approximately 75% of all adult women experience at least one episode of VVC in their lifetime.<sup>1,2</sup> Vulvovaginitis is defined as the inflammation of the vagina and vulva and includes symptoms like itching, burning, soreness, discharge, dyspareunia and signs like vaginal and vulvar erythema, edema and vaginal discharge.<sup>3</sup>

Though majority of the cases are caused by *Candida albicans*, the rest of the cases are due to non-albicans *Candida* species, like *C. glabrata*, *C. krusei* and *C. tropicalis*.<sup>2,4,5</sup> One of the most striking change in the current scenario is the increasing occurrence of non-albicans vulvovaginal candidiasis (VVC), which is considered as the major cause of recurrence, relapse and chronic VVC in India.<sup>6</sup> The prevalence of NAC was found to be as high as 60%.<sup>7</sup> While majority of adult women experience single episode of *Candida* vulvovaginitis, a small subpopulation may suffer from repeated episodes several times per year termed as recurrent VVC. And hence effective management

\* Corresponding author.

E-mail address: [dhiraj.dhoot@glenmarkpharma.com](mailto:dhiraj.dhoot@glenmarkpharma.com) (D. Dhoot).

of VVC play very important role which depends on accurate diagnosis; selection of specific therapy and good patient compliance.<sup>8</sup>

Though there are a variety of topical and systemic anti-fungal drugs available for the treatment of VVC still difficult to treat cases of vulvovaginal candidiasis in India are increasing. This possibly has been an outcome of a complex and intriguing interplay between host, fungus, drug and environment.<sup>8</sup> Because of this changing face of VVC in India, standard treatment recommendations from the Western and Indian literature are no longer valid. Majority of gynaecologists in India are relying on various experience-based treatment strategies such as higher dose of antifungal, longer duration of treatment etc. for the management of VVC. One such strategy is combination of systemic antifungal drug with intravaginal antifungal therapy. This has proven to be more effective with better clinical cure rate than systemic and topical alone in conventional dose and duration.<sup>6</sup>

We evaluated and compared therapeutic effectiveness of standard 1-day therapy (itraconazole 200 mg twice daily oral doses administered in the same day) and 3-day therapy (itraconazole 100 mg twice daily oral dose administered for three days) with 2-day therapy (itraconazole 200 mg twice daily oral dose administered for two days) in patients with acute VVC.

## 2. Materials and Methods

### 2.1. Patients

The present randomised, three arm comparative clinical study was conducted at two centres at Mumbai, India from May 2020 to December 2020 after obtaining ethics committee approval (ECR/644/Mh/Inst/2014/RR-17). A total of 123 women aged 18 years or above with symptomatic acute VVC were included in this study. Non-pregnant women who had clinical signs and symptoms of VVC (pruritus, burning, and discharge) and pseudo hyphae present on microscopic examination of a KOH smear were considered for enrolment in this study.

Women with any of the following conditions were excluded from the study: Pregnant or nursing females; women with history of chronic or recurrent VVC and hypersensitivity to azole drugs; women who were known to have diabetes or immunosuppression; women who have received antifungal chemotherapy in past one month; women who were known to have impaired renal or hepatic function; and women with history of concurrent bacterial, viral, or trichomonal vaginal infection. Control examination (1 week from baseline) encompassed assessment of symptoms and signs, and evaluation of side effects if any.

### 2.2. Mycological examination

In all patients, the diagnosis was confirmed by direct microscopy and KOH test at baseline. KOH was repeated at the end of therapy on day 7.

### 2.3. Therapy

After establishing the diagnosis, the patients were randomly divided into three groups of 41 each. The patients in Group 1 received total 400 mg of itraconazole orally divided into two doses of 200 mg on the same day. Group 2 received total 800 mg of itraconazole divided into two doses of 200 mg for 2 consecutive days. Three-day therapeutic regimen (Group 3) consisted of the total dose 600 mg of itraconazole divided into three oral 200 mg doses in three following days. The patients were instructed to take up itraconazole after meal with acid drink (cola, juice). Additionally, in all patients, intravaginal fenticonazole 600 mg on day 1 was given. The results were evaluated on the basis of clinical symptoms & signs and KOH. The occurrence of side effects was also followed up in these patients. After treatment, they were followed up on day 7 and each sign and symptom was assessed separately. On day 28, patients were asked about recurrence of any signs and symptoms.

### 2.4. Evaluation criteria

Clinical evaluation was consisting of physician assessment on 4 point Likert scale, which was designed for signs and symptoms of VVC like abnormal vaginal discharge, pruritus, dyspareunia, dysuria, erythema and odour. Score of 0 denotes no symptom whereas 1, 2, 3 were defined for mild, moderate and severe symptoms respectively. Based on this assessment, clinical effectiveness was recorded as cure, improvement, failure as follows:

1. Cure: Complete disappearance of all signs and symptoms (Total symptom score of 0) with a negative KOH;
2. Improvement: Improvement or partial disappearance of signs and symptoms (Improvement in symptom score by 50%) even if KOH was positive;
3. Failure: No change or worsening of signs and symptoms including positive KOH.

The present study was approved by Institutional Ethics committee and was conducted in accordance with recommendations and regulations of declaration of Helsinki and ICMR.

The statistical significance of the therapeutic outcome were assessed by the chi-square test. Relapse was evaluated clinically on day 28.


### 3. Results

After filtering through inclusion and exclusion criteria 123 patients were involved in the study and treated with oral itraconazole and intravaginal fenticonazole. Baseline demographics of these patients is shown in Table 1. Individual characteristics of all subgroups were similar and there were no statistically significant differences among these groups (Table 1).

**Table 1:** Baseline demographics

	Group I	Group II	Group III
<b>Number of patients</b>	41	41	41
<b>Age</b>			
Mean	33.51	33.29	32.6
SD	6.03	6.54	5.97
<b>Parity</b>			
Nulliparous	6	7	7
One child	25	23	26
Two children	8	6	4
Three children	2	5	4
<b>Contraceptives</b>			
None	8	10	10
IUD	15	9	6
Barrier	2	3	5
Hormonal	16	19	20
<b>Mean Symptom score</b>	7.48	7.41	7.43
<b>SD</b>	2.92	2.99	2.87

Complete cure i.e. complete absence of symptom/sign (total score=0) along with negative KOH was seen in 12% (5/41), 44% (18/41) and 17% (7/41) of patients respectively in Group 1, 2 and 3 (p value<0.05) (Figure 1).



**Fig. 1:** Number of patients showing cure, improvement and failure


The number of patients who achieved improvement at the end of treatment in groups I, II and III were 33/41 (80.5%), 23/41 (56%) and 31/41 (75.6%) respectively on physician's assessment (p<0.05). Total of 3 (7.3%) patients in Group I & III showed no change in signs and symptoms (Figure 1). Mycological cure i.e. negative KOH at day was maximum

in group II patients (49%), followed by group III (24%) and group I (17%) [Table 2].

**Table 2:** Mycological cure rate

	KOH at Day 7 =n (%)	
	Positive	Negative
<b>Group I</b>	34 (83%)	7 (17%)
<b>Group II</b>	21 (51%)	20 (49%)
<b>Group III</b>	31 (75%)	10 (25%)

In terms of mean symptom score, all the groups were effective in relieving signs and symptoms (p<0.05) at day 7 compared to baseline, but on comparison between all groups, there was statistical difference between Group II and Group I & III (p<0.05) and Group III & I (p<0.05) (Figure 2).



**Fig. 2:** Comparison of mean total symptom score at baseline and day 7


On individual symptom score, improvement in abnormal vaginal discharge (PVD) was more in group II as compared to other 2 groups and the difference was statistically significant (p<0.05). Improvement in pruritus was more in group II as compared to group I (p=0.01) and group III (p=0.127). Similarly, improvement in erythema was more in group II as compared to groups I and III (p=0.04). There was no statistically significant difference between the groups in other symptoms/sign as shown in Table 3.

On day 28, relapse was seen in 11 patients (27%) in Group I, 3 patients (7%) in Group II and 7 patients (17%) in Group III (Figure 3). On comparing, Group II was statistically significant than only Group I (p<0.05) but no statistical significant difference was found between Group II vs Group III (p=0.3) and Group I vs Group III (p=0.4).

All the patients completed the treatment. There were no adverse events in either of the three groups. All the three regimens were well tolerated.

**Table 3:** Improvement in mean individual symptom score

Symptom/sign	Group I	Group II	Group III	Overall p-value	Group comparison		
					I vs II	II vs III	I vs III
PVD	1.78 ± 0.08	2.41 ± 0.40	1.95 ± 0.12	<0.05	<0.0001	0.004	0.129
Pruritus	1.00 ± 0.76	1.48 ± 0.70	1.14 ± 0.78	0.05	0.01	0.127	0.162
Dyspareunia	0.19 ± 0.47	0.24 ± 0.61	0.29 ± 0.74	0.21	0.365	0.192	0.116
Dysuria	0.36 ± 0.40	0.58 ± 0.66	0.56 ± 0.60	0.14	0.132	0.451	0.158
Erythema	0.83 ± 0.67	1.02 ± 0.81	0.63 ± 0.83	0.04	0.04	0.04	0.5
Oedema	1.14 ± 0.93	1.17 ± 1.26	1.12 ± 0.96	0.36	0.461	0.427	0.469

**Fig. 3:** Percentage of patients with relapse at day 28

#### 4. Discussion

Vulvovaginal candidiasis is the second most common cause of vaginitis after anaerobic bacterial vaginosis. Although majority of the cases are caused by *C. albicans*, in recent years, there has been rise in non-albicans VVC.<sup>4</sup> The prevalence of NAC is increasing and it was found to be as high as 60% according to an Indian epidemiological studies.<sup>7,9–12</sup> NAC is less amenable to commonly used antifungal drugs in usual dose and duration.<sup>13</sup> In such cases, standard recommendations from Indian and western books are no longer valid and it becomes prudent to use combination of topical and systemic antifungal for complete clearance of the disease. Apart from this practice, many gynaecologists use high dose of itraconazole or any other antifungal for the treatment of VVC.

Itraconazole and fluconazole are safe, broad-spectrum antifungal drugs which have gained an important place in the treatment of vulvovaginal candidiasis. But due to increase in fluconazole non-responsiveness in VVC, caused by *Candida albicans* as well as NAC,<sup>13</sup> itraconazole has emerged as the preferred systemic antifungal drug of choice. One of the major reasons for such better effect of itraconazole in *Candida albicans* as well as NAC might be its “post antifungal effect”, which is persistence of antifungal action after reduction in dose/stoppage of antifungal drug<sup>14</sup> and better effect against NAC as well.<sup>6</sup>

In our study, we evaluated three regimens of itraconazole in the treatment of acute VVC. Complete cure and

clinical improvement was significantly more in Group II as compared to other groups. Additionally, relapse rate was lower in Group II than other groups. In one of the studies,<sup>15</sup> itraconazole was compared to fluconazole where 70% cure rate was found in itraconazole group. In another study,<sup>16</sup> on comparing two regimens of itraconazole (single day vs three day regime), no statistical difference was found between both the groups which is in corroboration with the findings of the present study.

Mycological cure rate in the present study was found to be 17%, 49%, and 25% in groups I, II and III, respectively. These findings were not corroborative with that of a western world study conducted by Spacek et al, wherein itraconazole was given in standard doses (corresponding to groups I and III of the present study). The mycological cure rate was found to be on higher side in this study.<sup>16</sup> Most probable reasons for such discrepant results might be the study period, since the study was done 15 years back and secondly, rise of NAC in current scenario has become a major hindrance in achieving good cure rates.

As compared to other published study, we have noticed less percentage of complete cure and high percentage of relapse rate in our study.<sup>16</sup> This might be due to multiple factors like dose and duration of itraconazole therapy and rise of NAC. Owing to these findings it can be anticipated that itraconazole therapy in high dose and prolonged duration will be more effective in increasing cure rates as compared to 1 day therapy, as is recommended in published literature.<sup>17,18</sup> This might explain best cure rates in group II as compared to others in the present study. Rise of NAC can also be an attributable factor for this finding, as it is well known that NAC is less susceptible to conventional antifungal drugs used for treatment of VVC.<sup>19</sup>

The pharmacokinetic aspects of itraconazole needs to be considered in this regard. Itraconazole follows non-linear pharmacokinetics and most significant consequence of non-linear pharmacokinetics is rapid accumulation of drug in tissues.<sup>20</sup> Secondly, at a high oral dose of itraconazole, absolute oral bioavailability (F) increases and there is increase in AUC<sub>0–48 h</sub>. As a result, the intestinal first-pass effect could be decreased by increasing oral doses of itraconazole.<sup>21</sup>

Secondly, itraconazole stays in the vaginal mucosa for longer period than other azoles because of its high

lipophilicity.<sup>15</sup> The highly lipophilic characteristic of itraconazole results in favourable tissue blood ratio.<sup>15,22</sup> As per one report, dosages of itraconazole 100-200 mg were associated with tissue concentrations that exceed corresponding plasma concentrations by up to 10-fold.<sup>21</sup> Also, it has been found that, itraconazole may remain in the vaginal tissue up to four days after a single-day treatment with 200mg twice a day.<sup>15,22</sup> Thus higher tissue concentration increases the likelihood of complete fungal eradication and hence reduction in relapses.<sup>15</sup>

In our study, in addition to itraconazole, we have used single dose of fenticonazole in all the patients. In view of rise in NAC, it is always better to use a drug which will be active against both, *Candida albicans* and NAC. Fenticonazole is one such drug which has many advantages like activity against all causative organisms of VVC, good safety and efficacy profile and a unique antifungal mechanism of action.<sup>23</sup>

Clinicians have a wide array of anti-fungal agents for the treatment of VVC but the single largest challenge to clinicians is achieving complete cure for the same. High clinical cure rates are the norm for uncomplicated VVC caused by *C. albicans* but the same cannot be said for NAC. All currently available anti-fungal agents achieve clinical improvement without in-parallel mycological eradication, warranting an ever-increasing number of patients colonized with *Candida* which can also serve as a reservoir for future episodes of VVC. Strategies like combination of topical and systemic anti-fungal agents or high dose/duration of anti-fungal agents are need of the hour to negate these challenges.

In our study, we tried combination therapy in all patients using different dosing schedule of itraconazole. Definitely, there are certain limitations of this study like small no. of patients and lack of culture of vaginal swab to confirm strain of *Candida* species. This necessitates further studies to validate our findings.

## 5. Conclusion

In the present study, 2 day high dose itraconazole therapy was found to have better effectiveness compared to conventional regimens. Still, the clinical and mycological cure rates were less in all three groups. Hence it can be anticipated that longer duration of therapy might be required to attain even better cure rates, especially when the incidence of Non *Albicans* vulvovaginal candidiasis is rising in all parts of the country.

## 6. Source of Funding

Not applicable.

## 7. Conflicts of Interest

None declared.

## 8. Ethical Approval

The study was approved by institutional ethics committee.

## References

- Sobel JD. Pathogenesis and Epidemiology of Vulvovaginal Candidiasis. *Ann N Y Acad Sci.* 1988;544(1):547–57. doi:10.1111/j.1749-6632.1988.tb40450.x.
- Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of *Candida* species causing vulvovaginitis and epidemiology of recurrent cases. *J Clin Micro-biol.* 2005;43(5):2155–62.
- Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated *Candida* vaginitis: Comparison of single and sequential doses of fluconazole. *Am J Obstet Gynecol.* 2001;185(2):363–9. doi:10.1067/mob.2001.115116.
- Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000?2004) epidemiological survey of *Candida* and non-*Candida* yeast species causing vulvovaginal candidiasis in Graz, Austria. *Mycoses.* 2006;49(6):471–5. doi:10.1111/j.1439-0507.2006.01284.x.
- Mahmoudabadi AZ, Najafyan M, Alidadi M. Clinical study of *Candida* vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. *Pak J Med Sci.* 2010;26(3):607–10.
- Kandhari S, Prabhat P, Rengarajan M, Dogra S, Nayak C, Banerjee D. Consensus on Management of Dermatophytosis and Vulvovaginal Infections in Non- Pregnant and Pregnant Females. *J Gynecol Obstet.* 2020;8(6):195–210.
- Kalia N, Singh J, Sharma S, Kamboj S, Arora H, Kaur M. Prevalence of Vulvovaginal Infections and Species Specific Distribution of Vulvovaginal Candidiasis in Married Women of North India. *Int J Curr Microbiol App Sci.* 2015;4(8):253–66.
- Costa M, Passos XS, Miranda AT, Dearaujo RS, Paula CR, Mdo RS. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. *Mycopathologia.* 2004;157:43–7.
- Ribeiro M, Dietze R, Paula C, Matta DD, Colombo A. Susceptibility profile of vaginal yeast isolates from Brazil. *Mycopathologia.* 2001;151:5–10.
- Ozcan SK, Budak F, Yucesoy G, Susever S, Willke A. Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. *APMIS.* 2006;114(2):139–45. doi:10.1111/j.1600-0463.2006.apm\_360.x.
- Ahmad A, Khan A. Prevalence of *Candida* species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. *Eur J Obstet Gynecol Reprod Biol.* 2009;144:68–71.
- Tilak R, Kumari V, Banerjee T, Kumar P, Pandey S. Emergence of non-*albicans* *Candida* among candidal vulvovaginitis cases and study of their potential virulence factors, from a tertiary care center, North India. *Indian J Pathol Microbiol.* 2013;56(2):144–7. doi:10.4103/0377-4929.118703.
- Makanjuola O, Bongomin F, Fayemiwo S. An Update on the Roles of Non-*albicans* *Candida* Species in Vulvovaginitis. *J Fungi.* 2018;4(4):121. doi:10.3390/jof4040121.
- Uchida K, Abe S, Yamaguchi H. The Postantifungal Effect (PAFE) of Itraconazole, in Comparison with Those of Miconazole and Fluconazole, on *Candida* Species. *Microbiol Immunol.* 2006;50(9):679–85. doi:10.1111/j.1348-0421.2006.tb03840.x.
- Tolasaria A, Nandi N. Efficacy of Itraconazole versus Fluconazole in Vulvovaginal Candidiasis: An in Vivo Study. *J Evol Med and Dent Sci.* 2014;3(29):7979–83. doi:10.14260/jemds/2014/2999.
- Spacek J, Buchta V. Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. *Mycoses.* 2005;48(3):165–71. doi:10.1111/j.1439-0507.2005.01099.x.

17. Young G, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. *Cochrane Database Syst Rev.* 2001;doi:10.1002/14651858.cd000225.
18. Sobel JD. Treatment of vaginal Candida infections. *Expert Opin Pharmacother.* 2002;3(8):1059–65. doi:10.1517/14656566.3.8.1059.
19. Deorukhkar S, Saini S. Non albicans Candida species: its isolation pattern, species distribution, virulence factors and antifungal susceptibility profile. *Int J Med Sci Public Health.* 2013;2(3):533–8. doi:10.5455/ijmsph.2013.080320131.
20. Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. *Expert Opin Drug Metab Toxicol.* 2013;9(7):911–26. doi:10.1517/17425255.2013.794785.
21. Shin JH, Choi KY, Kim YC, Lee MG. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. *Antimicrob Agents Chemother.* 2004;48(5):1756–62.
22. Quan M. Vaginitis: diagnosis and management. *Postgrad Med.* 2010;122:117–27.
23. Veraldi S, Milani R. Topical Fenticonazole in Dermatology and Gynaecology. *Drugs.* 2008;68(15):2183–94. doi:10.2165/00003495-

200868150-00007.

### Author biography

**Piyush Prabhat**, Senior Consultant

**Lalita Mayadeo**, Senior Consultant

**Harshal Mahajan**, Manager

**Dhiraj Dhoot**, Senior Manager

<p><b>Cite this article:</b> Prabhat P, Mayadeo L, Mahajan H, Dhoot D. Comparison of various regimens of itraconazole in treatment of acute vulvovaginal candidiasis. <i>Indian J Obstet Gynecol Res</i> 2021;8(2):244-249.</p>
---